On Wednesday, IPA’s stock was at $5.59. However, today it is gaining momentum: the stock is currently at $6.94, resulting in a 24% gain. The company today announced results from its TATX-03 PolyTope™ Therapy, a four monoclonal antibody cocktail created for the potential prevention and treatment of SARS-CoV-2, showing potent pseudovirus destroying activity against the SARS-CoV-2 Delta (B.1.617.2).
The company predicted viral evolution leading to novel SARS-CoV-2 variants of concern throughout the design of their PolyTope SARS-CoV-2 therapeutic cocktail, aiming to decrease the risk of mutagenic escape (a reduction or elimination in the efficacy of therapy or vaccine by virus mutation). As such, the company continuously legalizes, and has demonstrated to date, maintained neutralization potency of IPA’s multi-antibody cocktail towards SARS-CoV-2 variants of concern.
IPA previously told that TATX-03 demonstrated strong efficacy in reducing viral load in vivo using a hamster challenge model and potently neutralized pseudovirus of Alpha (B.1.1.7) and Beta (B.1.351) variants in vitro.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.